1. Academic Validation
  2. Small-Molecule Inhibition of UBE2T/FANCL-Mediated Ubiquitylation in the Fanconi Anemia Pathway

Small-Molecule Inhibition of UBE2T/FANCL-Mediated Ubiquitylation in the Fanconi Anemia Pathway

  • ACS Chem Biol. 2019 Oct 18;14(10):2148-2154. doi: 10.1021/acschembio.9b00570.
Matthew J Cornwell 1 Graeme J Thomson 2 Julia Coates 1 Rimma Belotserkovskaya 1 Ian D Waddell 2 Stephen P Jackson 1 Yaron Galanty 1
Affiliations

Affiliations

  • 1 The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry , University of Cambridge , Cambridge CB2 1QN , United Kingdom.
  • 2 Drug Discovery Unit, Cancer Research UK Manchester Institute , University of Manchester , Wilmslow Road , Manchester M20 4BX , United Kingdom.
Abstract

The Fanconi anemia pathway orchestrates the repair of DNA interstrand cross-links and stalled replication forks. A key step in this pathway is UBE2T and FANCL-dependent monoubiquitylation of the FANCD2-FANCI complex. The Fanconi anemia pathway represents an attractive therapeutic target, because activation of this pathway has been linked to chemotherapy resistance in several cancers. However, to date, very few selective inhibitors of ubiquitin conjugation pathways are known. By using a high-throughput screen-compatible assay, we have identified a small-molecule inhibitor of UBE2T/FANCL-mediated FANCD2 monoubiquitylation that sensitizes cells to the DNA cross-linking agent, carboplatin.

Figures
Products